Volatile.......Exciting......Liquid......Yep....That's MM, page-14

Posted this a while back but here's just an extract. Zynerba Pharmaceuticals is a clinical trial stage cannabis-based epilepsy treatment company much like Phytotech Therapeutics, MMJ's wholly owned subsidiary. GW Pharmaceuticals need no introduction.

GWPH:NASDAQ - 3.109 billion MC

ZYNE:NASDAQ - 265 million MC


Zynerba Pharmaceuticals: Undervalued Vs. GW Pharmaceuticals Plc
Feb. 23, 2017 11:27 AM•ZYNE
Summary

• Zynerba Pharmaceuticals and GW Pharmaceuticals Plc are late-stage biotech firms developing cannabidiol-based drugs for rare epileptic indications.
• The efficacy of cannabidiol in the treatment of epilepsy has been well-documented by both GW and recreational/medicinal users of marijuana where the drug is legalized.
• GW Pharmaceuticals' regulatory success represents positive news for both firms because the active ingredient in both Epidiolex and ZYN002 is identical.
• GW Pharmaceuticals is overvalued by any objective measure. And Zynerba, even in consideration of company specific risks, is undervalued in comparison.
• Zynerba represents a more compelling way to get in on the ground floor of the medical marijuana industry.

GW Pharmaceuticals Plc (NASDAQ:GWPH) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both developing cannabidiol-based pharmaceutical products for the treatment of orphan indication epileptic conditions. However, despite the similarity of these two firms, the market is treating them radically different in terms of valuation. We believe GWPH is overvalued and ZYNE is undervalued in comparison to the larger firm.

Today, at Matte's Micro-Cap Research, we will follow up our negative outlook for GW Pharmaceuticals Plc with a comparative analysis with Zynerba. If our last piece did not convince you of the problems with GWPH, this one should give further context to the thesis and present an alternative for investors who want to understand the other options in the space, specifically Zynerba Pharmaceuticals